Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Australian Clinical Labs Ltd ( (AU:ACL) ) has issued an update.
Australian Clinical Labs Ltd has announced a change in the director’s interest in securities. Stephen Roche, a director, has acquired 70,000 ordinary shares at $2.77 per share, marking his direct interest in the company through the Steann Superannuation Fund. This transaction, conducted on-market, indicates a significant personal investment by the director, potentially reflecting confidence in the company’s future performance.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.85 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Average Trading Volume: 1,046,126
Technical Sentiment Signal: Sell
Current Market Cap: A$536.5M
For a thorough assessment of ACL stock, go to TipRanks’ Stock Analysis page.